With the official launch of the 12th batch of national centralized drug procurement in 2026, the pharmaceutical industry has bid farewell to low-price competition. Quality priority, stable supply chain and cost performance have become the core criteria for terminal product selection. The cardiovascular chronic disease track maintains steady growth. As a classic core therapeutic drug, Diltiazem Hydrochloride features a large market base and stable repurchase demand. It serves as a high-quality product for terminal sales, community clinics, pharmacy chains and medical institutions.

Authorized Top Manufacturer & Reliable Premium Quality

This product is manufactured by DIVIS Laboratories, a leading pharmaceutical enterprise in India with 30 years of expertise in the global API industry. Its production facilities have passed authoritative certifications including US FDA, EU GMP and TGA, fully complying with ICH international pharmaceutical standards. Adopting a fully integrated industrial chain covering raw material synthesis and finished dosage formulation production, the company strictly controls impurities, crystal forms and drug stability. The product has achieved complete bioequivalence with the original reference drug, ensuring safe and stable long-term medication with reliable terminal reputation.

Wide Clinical Application & Rigid Market Demand

As a classic calcium channel blocker in cardiology, Diltiazem Hydrochloride is widely indicated for hypertension, coronary heart disease, angina pectoris, coronary vasospasm and supraventricular arrhythmia, delivering three core therapeutic effects: blood pressure reduction, coronary artery protection and heart rate stabilization. Different from similar drugs, it causes no reflex tachycardia, making it highly suitable for middle-aged and elderly patients with complicated chronic diseases. Widely recognized by doctors and patients, it is an essential drug for primary medical terminals with low market replacement resistance.

Core Investment Advantages: Stable Profit & Easy Market Promotion

✔Policy Compliance: Fully in line with the new centralized procurement policy focusing on stable supply. As a legally imported drug with complete qualifications and qualified port inspection reports, it is accessible for hospitals, chain pharmacies and primary medical markets.

✔Ultra-high Cost Performance: Large-scale standardized production eliminates excessive brand premium, delivering superior quality at a competitive price and balancing clinical efficacy and public affordability.

✔Controlled Pricing & Stable Profit: Exclusive regional agency policy with strict price and inventory control avoids market chaos and ensures sustainable profit margins for distributors.

✔Stable & Sufficient Supply: Mature global supply chain guarantees sufficient production capacity and timely delivery, effectively avoiding stockout risks and supporting sustainable terminal sales.

✔Effortless Sales Promotion: Rigid demand for chronic diseases, extensive patient coverage and high repurchase rate require minimal market education costs, enabling quick sales growth for new distributors.

Win the Market with Rigid Demand & Premium Products

In the new era of centralized procurement, product competition focuses on quality, compliance, profitability and supply stability rather than low prices. Imported Diltiazem Hydrochloride by DIVIS is backed by top-tier manufacturer quality, broad market potential and a sustainable profit model, making it a preferred incremental product for the 2026 pharmaceutical terminal market.